Our commitment to consumer healthcare
In consumer healthcare, Ipsen offers treatments for gastrointestinal disorders, neurodegenerative pathologies, and rheumatology.
Our commitment to endocrinology
Ipsen continues to develop innovative medicines in endocrinology, with specific investment in pituitary pathologies and growth disorders.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
- @IpsenGroup RT @G5Sante: @garidel_de : "Très bonne chose que nouvelle Ministre de la santé @agnesbuzyn connaisse parfaitement monde santé & recherche"…
- @IpsenGroup RT @G5Sante: T.Eckenschwiller (Ipsen Italie) : L'Italie a pour ambition de devenir 1er pays UE pour la production #pharma en Europe, devant…
- @IpsenGroup #phase3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced #HCC https://t.co/TcR1dTI3It
- @IpsenGroup #BREAKINGNEWS We are excited to continue membership w/ @PhRMA to boost R&D efforts for more innovative patient care… https://t.co/jLHtL0lvkC